Price
Financials
Standalone, Rs crore| Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5.39 | 9.67 | 8.89 | 7.44 | 8.41 | 12.49 | 5.52 | 8.92 | 6.45 | 4.15 | 5.58 |
| Expenses | 4.26 | 9.60 | 8.48 | 7.84 | 8.30 | 12.28 | 4.86 | 9.14 | 6.20 | 4.13 | 5.53 |
| Operating Profit | 1.13 | 0.07 | 0.41 | -0.40 | 0.11 | 0.21 | 0.66 | -0.22 | 0.25 | 0.02 | 0.05 |
| OPM % | 20.96% | 0.72% | 4.61% | -5.38% | 1.31% | 1.68% | 11.96% | -2.47% | 3.88% | 0.48% | 0.90% |
| Other Income | -0.02 | 0.02 | 0.20 | 0.09 | 0.01 | 0.02 | 0.05 | 0.33 | 0.04 | 0.05 | 0.07 |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
| Depreciation | 0.14 | 0.15 | 0.16 | 0.15 | 0.15 | 0.15 | 0.20 | 0.71 | 0.19 | 0.19 | 0.19 |
| Profit before tax | 0.96 | -0.07 | 0.44 | -0.47 | -0.04 | 0.07 | 0.50 | -0.61 | 0.10 | -0.13 | -0.08 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | 0.96 | -0.06 | 0.44 | -0.47 | -0.05 | 0.07 | 0.50 | -0.61 | 0.10 | -0.13 | -0.08 |
| EPS in Rs | 3.05 | -0.19 | 1.40 | -1.50 | -0.16 | 0.22 | 1.59 | -1.94 | 0.32 | -0.41 | -0.25 |
| TTM | |
|---|---|
| Sales | 25.10 |
| Expenses | 25.00 |
| Operating Profit | 0.10 |
| OPM % | 0.40% |
| Other Income | 0.49 |
| Interest | 0.03 |
| Depreciation | 1.28 |
| Profit before tax | -0.72 |
| Tax % | |
| Net Profit | -0.72 |
| EPS in Rs | -2.28 |
| Dividend Payout % |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | % | -26% | ||
| Compounded Profit Growth | % | % | % | -1540% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | % | % | % |
| Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | |
|---|---|---|---|---|---|---|---|
| Promoters | 34.43% | 34.43% | 34.43% | 39.36% | 39.36% | 39.36% | 39.36% |
| Public | 65.57% | 65.57% | 65.57% | 60.64% | 60.64% | 60.64% | 60.64% |
| No. of Shareholders | 2,386 | 2,386 | 2,386 | 2,295 | 2,295 | 2,295 | 2,295 |
Fundamentals
Market Cap₹ Cr.
Current Price₹
Book Value₹
ROCE%
ROE%
Dividend Yield%
Face Value₹ 10.0
Compounded Sales Growth (TTM)-26%
Compounded Profit Growth (TTM)-1540%
Standalone figures.
Ownership
Promoter holding39.36% (+4.93 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Dec 2015Sales ₹6 Cr +1.1% vs Dec 2014.
Net loss ₹0 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Pan Drugs Ltd?
Pan Drugs Ltd (531440) has a market capitalisation of Rs Cr. at the close.
What were Pan Drugs Ltd's latest quarterly results?
In the Dec 2015 quarter, Pan Drugs Ltd sales was Rs 6 Cr (+1.1% vs Dec 2014) with a net loss of Rs 0 Cr.